Dyadic International, Inc. (NASDAQ: DYAI) on "The Street Podcast" and Featured in Prestigious Science and Technology Journal - Tune In and Dive In!

Dyadic International, Inc. (NASDAQ: DYAI) Chief Executive Officer, Mark Emalfarb, appeared on "The Street Podcast" for an in-depth conversation about the company. During the interview, he highlighted that Dyadic had achieved success in creating an affordable, adaptable, and scalable protein production system, which the company subsequently sold to DuPont for $75 million. Also, CEO highlights C1 Platform's Game-Changing Impact Drawing Parallels to Tesla, Inc.'s (NYSE: TSLA) Automotive Industry Transformation among other 2024 company expectations. Listen Now! [https://thestreetreports.com/dyai-ceo-mark-emalfarb-shares-insights-6m-capital-raise-2024-outlook-etc-on-the-street-reports-podcast-tune-in/]

Image: https://www.abnewswire.com/uploads/1c26caff5c45bad866e5527b5948160d.jpg

Dyadic's stock has been consolidating in the mid $1.60's per share, representing a 21.48% increase March 2024. Currently, it is trading above its 10-day, 20-day, and 50-day moving averages (DMA), and is nearing its 200 DMA at $1.73 per share. If the stock surpasses its 200 DMA, it could potentially challenge its 52-week high of $2.40, making it a stock worth keeping an eye on in the near term.

Additionally, Dyadic International, Inc. (NASDAQ: DYAI) revealed the online publication of a manuscript titled "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models." This significant publication appeared in Nature Communications, a renowned global journal renowned for publishing peer-reviewed research across various science and technology domains. Read Journal Review Now! [https://www.nature.com/articles/s41467-024-46443-0]

The findings disclosed in the manuscript served as evidence of the promising potential of Dyadic International's C1 Expression system as a technology platform for human monoclonal antibody development and the production of therapeutic and preventive medications. This is the first trial using a C1-produced monoclonal antibody demonstrated comparable protection against SARS-CoV-2 in hamster and nonhuman primate models when compared to antibodies produced in CHO.

Furthermore, Dyadic recently concluded its participation in the Future Food Tech conference, emphasizing the advancement of sustainable and healthy food ecosystems. The event featured 1700 distinguished global food brands including Archer-Daniels-Midland Co. (NYSE: ADM), Kraft Heinz Co (NASDAQ: KHC), Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), Beyond Meat Inc. (NASDAQ: BYND), and others.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dyadic-international-inc-nasdaq-dyai-on-the-street-podcast-and-featured-in-prestigious-science-and-technology-journal-tune-in-and-dive-in]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.